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ABSTRACT
Introduction Mesothelioma remains a lethal cancer. 
To date, systemic therapy with pemetrexed and a 
platinum drug remains the only licensed standard 
of care. As the median survival for patients with 
mesothelioma is 12.1 months, surgery is an important 
consideration to improve survival and/or quality of life. 
Currently, only two surgical trials have been performed 
which found that neither extensive (extra- pleural 
pneumonectomy) or limited (partial pleurectomy) 
surgery improved survival (although there was some 
evidence of improved quality of life). Therefore, 
clinicians are now looking to evaluate pleurectomy 
decortication, the only radical treatment option left.
Methods and analysis The MARS 2 study is a 
UK multicentre open parallel group randomised 
controlled trial comparing the effectiveness and cost- 
effectiveness of surgery—(extended) pleurectomy 
decortication—versus no surgery for the treatment 
of pleural mesothelioma. The study will test the 
hypothesis that surgery and chemotherapy is superior 
to chemotherapy alone with respect to overall survival. 
Secondary outcomes include health- related quality 
of life, progression- free survival, measures of safety 
(adverse events) and resource use to 2 years. The 
QuinteT Recruitment Intervention is integrated into the 
trial to optimise recruitment.
Ethics and dissemination Research ethics approval 
was granted by London – Camberwell St. Giles 
Research Ethics Committee (reference 13/LO/1481) 
on 7 November 2013. We will submit the results for 
publication in a peer- reviewed journal.
Trial registration numbers ISRCTN—ISRCTN44351742 
and  ClinicalTrials. gov—NCT02040272.
Strengths and limitations of this study
 ► (Extended) pleurectomy decortication is currently 
offered to patients with mesothelioma on the United 
Kingdom National Health Service, but it is unknown 
whether it is a clinically beneficial or cost- effective 
treatment option. MARS 2 is the first randomised 
controlled trial to compare this type of surgery with 
no surgery in this patient population.
 ► Surgical quality assurance measures will be imple-
mented to ensure that the intervention will be deliv-
ered at centres with expertise.
 ► Patients may come with a pre- conceived perception 
that surgery will be beneficial, which can lead to 
crossovers (ie, patients allocated to no surgery may 
go on to seek surgery elsewhere). The integrated 
Quintet Recruitment Intervention supports recruit-
ment staff in responding to patient preferences and 
conveying balanced information.
 ► It is not possible to blind participants or the study 
team, but the primary outcome (survival) is objective.
 ► Patient pathways vary at different sites. Some flexi-
bility has been worked into the protocol to allow for 
this.
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INTRODUCTION
In the UK, approximately 2500 patients are diagnosed 
each year with pleural mesothelioma,1 a treatment- 
resistant and lethal cancer of the membranes lining the 
outer surface of the lung and the inside of the chest wall 
primarily due to asbestos exposure. Deaths are increasing 
yearly and are estimated to peak this year.2 So far, most 
treatments have proven ineffective. The current standard 
of care, consisting of 4 to 6 cycles of platinum and peme-
trexed chemotherapy, as recommended by the National 
Institute for Health and Care Excellence (NICE),3 has 
been associated with only an additional 3 months of 
survival.4 As the median survival for patients with meso-
thelioma is 12.1 months,4 surgery to remove as much of 
the disease as possible remains an important consider-
ation to improve survival and/or health- related quality of 
life (HRQoL).5
Pleurectomy decortication is the most common surgical 
procedure for mesothelioma worldwide and is defined 
as parietal and visceral pleurectomy to remove all gross 
tumour without diaphragm or pericardial resection.6 
Extended pleurectomy decortication can also be carried 
out, when parietal and visceral pleurectomy is undertaken 
to remove all gross tumour, including the resection of the 
diaphragm and/or pericardium. In the document we use 
the term (extended) pleurectomy decortication to refer 
to either of the two procedures. The other main types of 
surgery for mesothelioma are extra- pleural pneumonec-
tomy, which is defined as en bloc resection of the parietal 
and visceral pleura with the ipsilateral lung, pericardium 
and diaphragm (in cases where the pericardium and/or 
diaphragm are not involved by tumour, these structures 
may be left intact); and partial pleurectomy, which is 
the partial removal of parietal and/or visceral pleura for 
diagnostic or palliative purposes but leaving gross tumour 
behind.6
So far, no advantage, in terms of survival, has been 
observed with any type of surgery in randomised controlled 
trials (RCTs) conducted to date. The MARS feasibility 
study (ISRCTN95583524), a trial of extra- pleural pneu-
monectomy with adjuvant haemothorax irradiation, 
concluded that surgery was unlikely to offer either an 
improvement to survival or HRQoL and possibly harmed 
patients.7 MesoVATS (ISRCTN34321019) concluded that 
partial pleurectomy did not improve survival, although it 
showed that patients in the better prognostic group had 
improved HRQoL after 6 months.8
Suitable patients, both in the UK and internationally, 
are currently offered pleurectomy decortication as it is 
considered to carry less morbidity compared with the 
more extensive extra- pleural pneumonectomy but still 
achieves complete macroscopic resection which partial 
pleurectomy does not.9–11 However, we do not know if 
(extended) pleurectomy decortication in conjunction 
with chemotherapy will improve survival compared with 
the current standard of care (chemotherapy alone). In 
the absence of RCTs, (extended) pleurectomy decor-
tication may continue to be offered despite a lack of 
high- quality evidence of clinical efficacy or any evidence 
on cost- effectiveness.
Aims and objectives
MARS 2 is a UK- wide multicentre RCT which will test the 
hypothesis that (extended) pleurectomy decortication 
and chemotherapy is superior to chemotherapy alone 
with respect to overall survival for patients with pleural 
mesothelioma.
Specific objectives are to estimate:
A. The difference between groups in overall survival.
B. The difference between groups with respect to a 
range of secondary outcomes including HRQoL, 
progression- free survival and measures of safety (ad-
verse health events).
C. The cost- effectiveness of (extended) pleurectomy de-
cortication compared with no surgery.
METHODS AND ANALYSIS
Trial design
MARS 2 is a multicentre, non- blinded parallel two- 
group, pragmatic RCT of surgery and chemotherapy 
versus chemotherapy alone for suitable patients with 
mesothelioma.
An internal pilot funded by Cancer Research UK (award 
ref: C27967/A15895) and coordinated by the Papworth 
Trials Unit Collaboration demonstrated the feasibility of 
recruitment across 14 medical sites and 2 joint medical 
and surgical sites of excellence, as the target of 50 partic-
ipants recruited within a 24- month period was achieved.
Since the end of the pilot phase in December 2016, 
an additional eight medical, one surgical, and two joint 
medical and surgical sites have been opened for the full 
trial. In addition, the full trial will provide recruiting sites 
with the support of an integrated QuinteT Recruitment 
Intervention (QRI)12–14 to optimise recruitment and 
retention.
Setting, centre and surgeon eligibility
This study is taking place in National Health Service 
(NHS) secondary care centres, including teaching and 
district general hospitals.
To be eligible as a medical site, the centre must:
1. Be an NHS Trust with access to a multidisciplinary 
team (MDT) to discuss patients with mesothelioma.
2. Have a track record of treating patients with 
mesothelioma.
To be eligible as a surgical site, the centre must:
1. Be an NHS Trust with an established mesothelioma 
MDT.
2. Have a minimum of two named mesothelioma sur-
geons participating in the trial.
All surgeons participating in the full trial must be 
accredited by (1) self- reporting a minimum of five cases 
in which they have performed (extended) pleurectomy 
decortication, (2) observing the procedure being under-
taken at an established MARS 2 surgical site, (3) having 
a surgeon from the pilot phase observe their first MARS 
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2 procedure undertaken and (4) having one randomly 
selected MARS 2 operation between procedures 5 and 
10 observed by a surgeon from the pilot phase to ensure 
fidelity.
Patients from all medical (only) sites are referred to a 
trial- accredited surgical site for CT assessment of eligi-
bility, further discussion about the study and surgery (if 
randomised to this group).
Trial population
The target population are patients with a diagnosis of 
epithelioid, sarcomatoid or biphasic mesothelioma. 
Patients will be eligible to take part if ALL of the following 
apply:
 ► Adult aged ≥16 years of age.
 ► Tissue (cytology or histology) confirmed epithelioid, 
sarcomatoid or biphasic mesothelioma, as reviewed 
by MDT to be of sufficient certainty to recommend 
chemotherapy as treatment.
 ► Disease confined to one hemithorax based on CT 
assessment.
 ► Disease deemed surgically resectable by a surgeon at a 
MARS 2 surgical site.
 ► Deemed fit for surgery by a surgeon at a MARS 2 
surgical site.
 ► Capacity to provide written informed consent to 
participate in the trial.
Patients will not be eligible if they have:
 ► Severe shortness of breath (Eastern Cooperative 
Oncology Group status ≥2, or preoperative FEV1 or 
TLco less than 20%).
 ► Severe heart failure (NYHA III or IV, or ejection frac-
tion less than 30% by echocardiogram).
 ► End- stage kidney failure requiring dialysis.
 ► Liver failure (eg, encephalopathy and/or coagulation 
abnormalities).
 ► Any other serious concomitant disorder that would 
compromise participant safety during surgery.
 ► Prisoner.
 ► Patient lacks capacity to consent.
 ► Existing co- enrolment in another interventional study 
that aims to improve survival.
Patient approach, consent and randomisation
The local research team at the medical site will take 
written informed consent from participants. In addi-
tion to the main study, the team may also seek consent 
for audio- recording of consultations and participation 
in interviews, for QRI purposes. Participants will then 
receive two cycles of chemotherapy (standard care) and 
have a further CT scan to confirm eligibility (ie, disease 
still resectable) before being randomised, using a secure 
web- based randomisation system (Sealed Envelope 
https:// sealedenvelope. com).
Participants will be randomised in a 1:1 ratio. Mini-
misation (with a random component) will be applied 
for selected baseline variables (age, performance status 
and cell type) that influence survival, in addition to 
stratification by recruiting site to ensure that the cohorts 
are as balanced as possible.
Trial interventions
Patients will be randomised to receive one of the following 
interventions:
 ► (Extended) pleurectomy decortication and chemotherapy: two 
cycles of platinum and pemetrexed chemotherapy 
followed by surgery and then up to four cycles of the 
same chemotherapy.
 ► Chemotherapy alone (control intervention): up to six cycles 
of platinum and pemetrexed chemotherapy alone 
(current standard of care).
The trial schema is illustrated in figure 1.
After randomisation, any changes in the choice of 
chemotherapy, addition of other agents or entry into ther-
apeutic trials (eg, immunotherapies) will be permitted 
for patients with progressive disease. At the time of trial 
design, there was no national consensus on postoperative 
prophylactic radiotherapy, so it was decided that irradia-
tion to thoracic procedure sites may be undertaken for 
MARS 2 patients. Patients in both groups can also receive 
further surgery, including thoracic, if it is without radical 
intent. The aim is to conduct a pragmatic trial while 
closely monitoring uptake of additional therapies, studies 
or surgeries in order to account for them in the trial anal-
yses, if required.
Primary and secondary outcomes
The primary outcome is survival, calculated from rando-
misation date (randomisation occurs after the first two 
cycles of chemotherapy). All participants will be followed 
up to the end of the trial (minimum of 2 years after 
randomisation).
Secondary outcomes have been selected to assess the 
efficacy of the two approaches. Secondary outcomes 
are (1) progression- free survival to the end of the trial 
(minimum of 2 years after randomisation); (2) serious 
adverse health events to 2 years after randomisation; (3) 
disease- specific and generic HRQoL using the following 
validated questionnaires—European Organisation for 
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ- C30), to assess the HRQoL of 
patients with cancer, and EuroQol EQ- 5D- 5L,15 16 a widely 
used generic measure of HRQoL (both of these will be 
measured at baseline, pre- randomisation, and 6 weeks, 6, 
12, 18 and 24 months post- randomisation); and (4) health-
care resource use to the end of the study: chemotherapy 
cycles and initial surgical admission (for chemotherapy 
plus surgery group), and further resources measured at 
6 weeks post- randomisation then every 6 months, with a 
final follow- up at the end of the study if not followed up 
in the previous 4 months.
Data collection
The schedule for data collection for the study is shown 
in table 1. Data will be collected onto purpose- designed 
case report forms (CRFs) and participant- completed 
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questionnaires and entered onto a bespoke database for 
data cleaning and analysis. Access to the database will be 
via a secure password- protected web interface hosted on 
an NHS server. Data about adverse events will be collected 
and reported in accordance with sponsor’s and regula-
tory requirements.
Risk of bias
Participants and clinical personnel cannot be blinded 
to allocation due to the nature of the study interven-
tion. However, standard local protocols will be followed 
in terms of patient care. The patient information leaflet 
and conversations with MARS 2 site staff will describe and 
balance the potential benefits and risks of both having 
and not having surgery. Therefore, this approach will 
reduce participant’s expectations that one or other treat-
ment protocol will lead to a more favourable result.
In addition, the study’s primary outcome is an objec-
tive measure (survival), and clear definitions of each 
secondary outcome measure will be provided to trial 
personnel. The HRQoL follow- up questionnaires may 
be more at risk of bias than other measures, but patients 
will not have had this surgery previously and as such 
should not have any expectation regarding its effect on 
their HRQoL. Missing outcome data will be minimised, 
as survival and progression- free survival data can be 
obtained from hospital records. Losses to follow- up will 
be minimised by maintaining regular contact with partic-
ipants (by telephone and post) to complete follow- up 
questionnaires. Non- adherence to randomised allocation 
will be documented. Bias in the reported results will be 
minimised by having pre- specified outcomes in the trial 
protocol and a pre- specified analysis plan.
Sample size
The total sample size has been set at 328 participants (164 
per group). The patients randomised in the pilot trial will 
contribute to the total sample size. The study will have 
80% power to detect a HR of 0.7 at 5% statistical signifi-
cance (two- sided), modelled on a published assumption 
of a median survival time of 16.8 months in patients with 
mesothelioma who were fit enough to receive surgery, but 
did not have it17 and allowing for 10% cross- over from 
the medical to surgery groups (as noted in previous trials 
such as MARS).7 Cross- over will be minimised through 
instruction (ie, recruit only patients who have equipoise 
from the outset) and education.
Figure 1 Trial schema showing the recruitment pathway for the MARS 2 study.
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The relative difference of 30% (HR 0.7) was regarded 
as the minimally important difference for patients and 
clinicians to choose surgery given the risks of the proce-
dure. The figure was chosen by the trial’s patient and 
public involvement (PPI) group. The possibility that 
survival could be worse with surgery was also discussed, 
and a relative difference of 30% was also regarded as an 
appropriate difference to indicate harm, therefore a two- 
tailed test for superiority was agreed.
Patient and public involvement
Patient and public representatives were involved from 
inception and advised on the trial design of MARS 2, the 
identification of the choice of the primary outcome and 
defined the minimally important difference in relative 
survival.
The study team have continuing engagement with the 
Royal Brompton Hospital Cancer Consortia PPI group, 
which consists of patients and carers who have under-
gone surgery for lung cancer and mesothelioma, to 
advise on patient- orientated questions that arise from the 
trial conduct. One patient from the PPI group, a meso-
thelioma survivor, has agreed to sit on the Trial Steering 
Committee. The PPI group will also be involved in the 
dissemination of study results.
Integrated QRI
Recruitment to RCTs can be challenging,18 particularly 
for surgical trials.19 An integrated QRI will therefore 
be employed during the main study phase to optimise 
recruitment and retention. The aim of the QRI is to 
understand the recruitment process and how it operates 
in clinical centres, so that sources of recruitment difficul-
ties can be identified, and suggestions made to change 
aspects of design, conduct, organisation or training.
A multi- faceted, flexible approach will be used to inves-
tigate site- specific or wider recruitment obstacles. These 
will comprise the following:
 ► Mapping of eligibility and recruitment pathways to 
collate basic data about the levels of eligibility and 
recruitment, and identify points at which patients opt 
in or out of the trial.
 ► In- depth, semi- structured interviews with a purposive 
sample of staff members involved with aspects of trial 
design/management and recruitment across centres, 
and patients eligible for recruitment to the trial. Inter-
views will explore participants’ perspectives of the 
trial, views on the presentation of study information, 
understanding of trial processes (eg, randomisation), 
and reasons underlying decisions to accept or decline 
the trial. In addition, interviews with staff and other 
individuals involved in the trial will explore perspec-
tives on the trial design and protocol, views about 
the evidence on which the trial is based, perceptions 
of uncertainty/equipoise for themselves and their 
colleagues, methods for identifying eligible patients, 
views on eligibility, and examples of actual recruit-
ment successes and difficulties. Interview topic guides 
will be used to ensure similar topic areas are covered 
across interviews, while still providing the scope for 
participants to raise issues of pertinence to them.
 ► Audio- recording of consultations between healthcare 
staff and potentially eligible patients across centres to 
understand the recruitment process at each centre 
and to identify and investigate the challenges to 
recruitment. The QRI researcher will listen to and 
qualitatively analyse the appointments, documenting 
instances such as unclear, insufficient or imbalanced 
information provision and unintentional transferring 
of clinician treatment preferences to patients.
 ► Observation of Trial Management Group (TMG) 
and investigator meetings to gain an overview of trial 
conduct and overarching challenges (logistical issues, 
etc).
An account of the anonymised findings from all 
the data will be fed back to the Chief Investigator and 
TMG. The data will be used by the QRI team to provide 
supportive and confidential individual and group feed-
back to recruiters to help them to communicate equi-
poise, balance treatment options and explain to patients 
the benefits and purposes of trial participation, while 
optimising informed consent.
Statistical analyses
The data will be analysed for randomised patients 
according to intention to treat and follow Consolidated 
Standards of Reporting Trials (CONSORT) guidelines. 
Analyses will be adjusted for site and for design factors 
included in the cohort minimisation (eg, age, perfor-
mance status and cell type).
Survival time and progression- free survival time from 
randomisation will be compared using survival methods, 
allowing for censoring of any participant who is either 
alive or lost to follow- up at the end of the follow- up period. 
Patient- reported outcome scores (HRQoL EQ- 5D- 5L 
and QLQ- C30) will be compared using a mixed regres-
sion model and adjusted for baseline measures where 
appropriate. Changes in treatment effect with time will 
be assessed by adding a treatment × time interaction to 
the model and comparing models using a likelihood ratio 
test. Deaths will be accounted for by modelling survival 
and HRQoL jointly. Model fit will be assessed using 
standard methods and alternative models and/or trans-
formations will be explored if appropriate. Treatment 
differences and 95% CIs will be reported.
Missing data on patient questionnaires will be dealt 
with according to the scoring manuals. Multiple imputa-
tion methods will be used if greater than 5% of cases have 
missing data, otherwise complete case analysis will be 
undertaken. Compliance rates will be reported, including 
the number of participants who have withdrawn from the 
study, have been lost to follow- up or died. Causes of death 
for trial participants will be recorded.
Frequencies of adverse events will be described. The 
proportion of participants experiencing one or more 
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serious adverse events in the follow- up period will be 
compared using a generalised linear model.
Two subgroup analyses are planned: (1) comparing 
primary and secondary outcomes by the experience level 
of the surgical site; (2) comparing the primary outcome 
by type of mesothelioma (epithelioid, sarcomatoid or 
biphasic). An exploratory analysis investigating the effect 
of surgeon (surgical group only) will be performed for 
the primary outcome.
No interim analyses are planned. The primary analysis 
will take place when follow- up is complete for all recruited 
participants.
Economic evaluation
The economic evaluation will compare the costs and 
effects of surgery versus no surgery, following estab-
lished guidelines as set out by NICE.20 The within- trial 
cost- effectiveness analysis will be undertaken from an 
NHS and personal social services perspective, with a 
time horizon from time of consent to 24 months post- 
randomisation. The primary outcome measure for the 
economic evaluation will be quality- adjusted life years 
(QALYs), estimated using the EuroQol EQ- 5D- 5L at each 
follow- up timepoint.15 16 Resource use data collection will 
be integrated into the trial CRFs for chemotherapy cycles 
and surgery (if applicable, this will include details of the 
surgical procedure, length of stay in hospital by level of 
care, and postoperative complications) and be collected 
at each follow- up timepoint.
Unit costs will be sought to value resource use data, 
and the total costs per participant calculated. Responses 
to the EQ- 5D- 5L will be assigned valuations according to 
NICE guidance at the time of analysis,21 and combined 
with survival to calculate QALYs gained per participant. 
Missing resource use and EQ- 5D- 5L data will be handled 
using multiple imputation methods.22 From the average 
costs and QALYs gained in each trial group, the incre-
mental cost- effectiveness ratio will be derived, producing 
an incremental cost per QALY gained of surgery 
compared with no surgery. Sensitivity analyses will assess 
the impact of varying key parameters on baseline cost- 
effectiveness results. Results will be expressed in terms of 
a cost- effectiveness acceptability curve, which indicates 
the likelihood that surgery is cost- effective for different 
levels of willingness to pay for health gain.
Ethics and dissemination
The study intervention is already routinely used in the 
NHS. The pilot study was managed by Papworth Trials 
Unit Collaboration and the main trial is managed by 
the Bristol Trials Centre Clinical Trials and Evaluation 
Unit and sponsored by Royal Brompton & Harefield 
NHS Foundation Trust. Each participant has the right to 
withdraw at any time. In addition, the investigator may 
withdraw the participant from their allocated treatment 
group if a clinical reason for not performing the surgical 
intervention is discovered. If a participant wishes to with-
draw, any data already collected will be included in the 
study analyses, unless the participant expresses a wish for 
their data to be excluded. Withdrawing patients will be 
asked if they would continue in follow- up and complete 
the requisite questionnaires. Participants who choose to 
withdraw from the study will be treated according to their 
hospitals’ standard procedures.
The findings will be disseminated by usual academic 
channels, that is, presentation at international meetings 
and peer- reviewed publications. A full report for the 
funder will be written on completion of the study and a 
lay summary of the results provided to patients.
Major changes to protocol
Since the first study protocol was approved by the 
Research and Ethics Committee (the current version is 
V.6.0, 10 April 2019), the following changes have been 
made:
 ► Qualitative assessment substudy added, as part of the 
pilot phase only.
 ► The EuroQol EQ- 5D- 5L was added.
 ► Updates to transition from pilot phase to main 
study, including addition of the integrated QRI and 
economic evaluation, and removal of the collection 
of blood and tissue samples, and one of the disease- 
specific questionnaires—the EORTC QLQ LC-13.
 ► Length of follow- up extended from 2 years until the 
end of the study for all participants to ensure that the 
study has 80% power.
 ► Video- recording aspect of the surgical quality assur-
ance removed as this was deemed impractical by 
sites, and it was agreed that it was unnecessary by 
the Data Safety and Monitoring Committee and the 
Trial Steering Committee, acknowledging the other 
surgical quality assurance measures that are in place.
Study progress
Recruitment started in May 2015 and 308 patients have 
been randomised so far (correct on 25 May 2020). A total 
of 66 patients from the pilot study are included in this 
figure. Recruitment will continue until 30 September 
2020.
The full protocol is available online (https://www. jour-
nalslibrary. nihr. ac. uk/ programmes/ hta/ 1518831/).
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